Security key
87184Q107
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS)
CUSIP: 87184Q107
Q2 2022 13F Holders as of 30 Jun 2022
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 35,563,928
- Total 13F value
- $34,226,317
- Share change
- -9,010,846
- SEC-reported price per share
- $0.96
- Number of holders
- 58
- Value change
- -$9,550,880
- Number of buys
- 26
- Number of sells
- 57
- Shares outstanding
- 27,995,500
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2022
Institutions
58
Top holders
10
SYRS full security history
Ownership snapshot
Full 13F holder table
Syros Pharmaceuticals, Inc. SEC filings
Syros Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
0/15
Latest evidence
31 Mar 2022
13F
Highest disclosed value: $7,455,000
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC has the largest disclosed position value at $7.46M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Disclosed position value
Top 5
Bain Capital Life Sciences Invest...
$7.46M
BlackRock Finance, Inc.
$4.96M
Artal Group S.A.
$4.16M
Ally Bridge Group (NY) LLC
$4M
Flagship Pioneering, LLC
$3.5M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
—
denominator unverified
|
$7,455,000
6,264,420 shares
|
— | 31 Mar 2022 |
| BlackRock Finance, Inc. |
13F
Company
|
—
denominator unverified
|
$4,963,000
4,170,141 shares
|
— | 31 Mar 2022 |
| Artal Group S.A. |
13F
Company
|
—
denominator unverified
|
$4,165,000
3,500,000 shares
|
— | 31 Mar 2022 |
| Ally Bridge Group (NY) LLC |
13F
Company
|
—
denominator unverified
|
$4,004,000
3,364,895 shares
|
— | 31 Mar 2022 |
| Flagship Pioneering, LLC |
13F
Company
|
—
denominator unverified
|
$3,497,000
2,938,494 shares
|
— | 31 Mar 2022 |
| Omega Fund Management, LLC |
13F
Company
|
—
denominator unverified
|
$2,990,000
2,512,705 shares
|
— | 31 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
58
Shares
35,563,928
Rows available
58
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
86
Q2 2022 holders
58
Holder diff
-28
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 value | Q2 2022 value | Value change | Value Chg % |
|---|